Top 25 Deep Learning Applications Used Across Industries

Meta Is Creating A New A.I. Lab To Pursue 'Superintelligence'

Meta is preparing to unveil a new artificial intelligence research lab dedicated to pursuing "superintelligence," a hypothetical A.I. System that exceeds the powers of the human brain, as the tech giant jockeys to stay competitive in the technology race, according to four people with knowledge of the company's plans.

Meta has tapped Alexandr Wang, 28, the founder and chief executive of the A.I. Start-up Scale AI, to join the new lab, the people said, and has been in talks to invest billions of dollars in his company as part of a deal that would also bring other Scale AI employees to the company. Meta has offered seven- to nine-figure compensation packages to dozens of researchers from leading A.I. Companies such as OpenAI and Google, with some agreeing to join, according to the people.

The new lab is part of a larger reorganization of Meta's A.I. Efforts, the people said. The company, which owns Facebook, Instagram and WhatsApp, has recently grappled with internal management struggles over the technology, as well as employee churn and several product releases that fell flat, two of the people said.

Mark Zuckerberg, Meta's chief executive, has invested billions of dollars into turning his company into an A.I. Powerhouse. Since OpenAI released the ChatGPT chatbot in 2022, the tech industry has raced to build increasingly powerful A.I. Mr. Zuckerberg has pushed his company to incorporate A.I. Across its products, including in its smart glasses and a recently released app, Meta AI.

Staying in the race is crucial for Meta, Google, Amazon and Microsoft, with the technology likely to be the future for the industry. The giants have pumped money into start-ups and their own A.I. Labs. Microsoft has invested more than $13 billion in OpenAI, while Amazon has plowed $8 billion into the A.I. Start-up Anthropic.

The behemoths have also spent billions to hire employees from high-profile start-ups and license their technology. Last year, Google agreed to pay $3 billion to license technology and hire technologists and executives from Character.AI, a start-up that builds chatbots for personal conversations.

We are having trouble retrieving the article content.

Please enable JavaScript in your browser settings.

Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.

Thank you for your patience while we verify access.

Already a subscriber? Log in.

Want all of The Times? Subscribe.

F.D.A. To Use A.I. In Drug Approvals To 'Radically Increase Efficiency'

The Food and Drug Administration is planning to use artificial intelligence to "radically increase efficiency" in deciding whether to approve new drugs and devices, one of several top priorities laid out in an article published Tuesday in JAMA.

Another initiative involves a review of chemicals and other "concerning ingredients" that appear in U.S. Food but not in the food of other developed nations. And officials want to speed up the final stages of making a drug or medical device approval decision to mere weeks, citing the success of Operation Warp Speed during the Covid pandemic when workers raced to curb a spiraling death count.

"The F.D.A. Will be focused on delivering faster cures and meaningful treatments for patients, especially those with neglected and rare diseases, healthier food for children and common-sense approaches to rebuild the public trust," Dr. Marty Makary, the agency commissioner, and Dr. Vinay Prasad, who leads the division that oversees vaccines and gene therapy, wrote in the JAMA article.

The agency plays a central role in pursuing the agenda of the U.S. Health secretary, Robert F. Kennedy Jr., and it has already begun to press food makers to eliminate artificial food dyes. The new road map also underscores the Trump administration's efforts to smooth the way for major industries with an array of efforts aimed at getting products to pharmacies and store shelves quickly.

Some aspects of the proposals outlined in JAMA were met with skepticism, particularly the idea that artificial intelligence is up to the task of shearing months or years from the painstaking work of examining applications that companies submit when seeking approval for a drug or high-risk medical device.

"I don't want to be dismissive of speeding reviews at the F.D.A.," said Stephen Holland, a lawyer who formerly advised the House Committee on Energy and Commerce on health care. "I think that there is great potential here, but I'm not seeing the beef yet."

We are having trouble retrieving the article content.

Please enable JavaScript in your browser settings.

Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.

Thank you for your patience while we verify access.

Already a subscriber? Log in.

Want all of The Times? Subscribe.

For Some Recent Grads, The AI Job Apocalypse May Already Be HereAnalysis

ERROR: The request could not be satisfied

Request blocked. We can't connect to the server for this app or website at this time. There might be too much traffic or a configuration error. Try again later, or contact the app or website owner. If you provide content to customers through CloudFront, you can find steps to troubleshoot and help prevent this error by reviewing the CloudFront documentation.

Generated by cloudfront (CloudFront) Request ID: uT_w1PvU-cFM32JckValrorW0VDKXI8l2Q_A-EFNcqKNg6zWL7qohQ==

---